Paolo Bironzo

13PUBLICATIONS
157CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Dec 17, 2025
Correction: Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy.

Fabiana Letizia Cecere, Ettore D'Argento, Francesco Gelsomino

|Dec 12, 2025
Rucaparib in refractory pleural mesothelioma harboring somatic pathogenic BRCA1 and BRCA2 mutation. A report of two cases.

Luigi Cerbone, Benedetta Del Rio, Sara Delfanti

|Nov 17, 2025
Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy.

Fabiana Letizia Cecere, Ettore D'Argento, Francesco Gelsomino

|Jan 21, 2025
De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence?

Jordi Remon, Martina Bortolot, Paolo Bironzo

|Jan 26, 2024
Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade.

Andriani Charpidou, Grigorios Gerotziafas, Sanjay Popat

|Dec 18, 2023
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial.

Francesco Passiglia, Luisella Righi, Paolo Bironzo

Pageof 3

Frequent Collaborators

5 joint publications

Luisella Righi

4 joint publications

Silvia Novello

4 joint publications

Giorgio Vittorio Scagliotti

2 joint publications

Annapaola Mariniello